Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Saved in:
| Title: | Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). |
|---|---|
| Authors: | Miyake M; Department of Urology, Nara Medical University, Nara, Japan. |
| Source: | International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2024 Mar; Vol. 31 (3), pp. 273. Date of Electronic Publication: 2024 Jan 03. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1442-2042 |
|---|---|
| DOI: | 10.1111/iju.15384 |
